CARL vs CRL · rev $50.5M vs rev $2.00B
Carlsmed, Inc. Common Stock (CARL) versus Charles River Laboratories (CRL) — a side-by-side from cached financials, not a winner call.
Carlsmed, Inc. Common Stock (CARL) is a health information services company listed on NASDAQ.
Charles River Laboratories (CRL) is a diagnostics & research company listed on US.
Latest reported CARL revenue for 2025-12-31 was $50.5M. Net income was -$29.6M. Revenue was up 85.9% from 2024-12-31 to 2025-12-31. CARL currently screens at market cap $299.7M.
Latest reported CRL revenue for 2026-06-27 was $2.00B. Net income was -$16.3M. CRL currently screens at market cap $7.78B.
CARL currently screens at market cap $299.7M. CRL currently screens at market cap $7.78B.
Not investment advice. Open the CARL and CRL stock pages for the full models.
Not investment advice.